Daratumumab/Lenalidomide/Dexamethasone until progression clinical trials

Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

This study looks at treating a type of cancer called multiple myeloma that has come back. It compares how long people take a drug combination (Dara-Len-Dex) – either for a set time (2 years) or until the cancer gets worse. The main goal is to see which approach helps people live longer.